Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) just released its latest yearly report and things are not looking great. It was...
Ocuphire Pharma ( NASDAQ:OCUP ) Full Year 2023 Results Key Financial Results Revenue: US$19.0m (down 52% from FY 2022...
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts, pav